Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

Blog Article

After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan.Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors.The Japan Association for Diabetes Education and Care (JADEC) released a recommendation in April 2010 to lower the dose of three major SUs (glimepiride, glibenclamide, and gliclazide) when adding a DPP-4 inhibitor.

To evaluate the effectiveness of this risk minimization action along with labeling changes, dispensing records for 114,263 patients prescribed OHDs Pot Holder between December 2008 and December 2010 were identified in the Nihon-Chouzai pharmacy claims database.The adherence to the recommended dosing of SU co-prescribed with DPP-4 inhibitors increased from 46.3% before to 63.

8% after the JADEC recommendation (p < 0.01 by time-series analysis), while no change was found in those for SU monotherapy and SU with other OHD co-prescriptions.The adherence was significantly worse for those receiving a glibenclamide prescription.

The JADEC recommendation, along with labeling changes, appeared to Files have a favorable effect on the risk minimization action in Japan.In these instances, a pharmacy claims database can be a useful tool to evaluate risk minimization actions.